Year 2020 / Volume 112 / Number 7
Original
Changes in the characteristics of hospital admissions due to decompensated cirrhosis in the era of direct-acting antivirals against hepatitis C virus

538-544

DOI: 10.17235/reed.2020.7024/2020

Miguel Fraile López, Lissa Franco, Carmen Álvarez Navascués, María Varela, Valle Cadahía, María Torner, Ana Gómez Outomuro, María Luisa González-Diéguez, Manuel Rodríguez García,

Abstract
Background: the development of interferon-free regimens, based on direct acting antivirals (DAAs) has revolutionized the treatment of hepatitis C virus (HCV) infection. Aims: to determine if there have been changes in the characteristics of hospital admissions due to decompensated cirrhosis in a general hospital since the introduction of DAAs. Patients and methods: this was a prospective study of all hospital admissions due to decompensated cirrhosis during two periods: October 2012-October 2014 (P-I) and July 2016-July 2018 (P-II). Clinical and demographic variables were collected and standard statistical methods were used for the analysis. Results: there were 746 hospital admissions; 347 in P-I and 399 in P-II. P-I patients were younger (59 vs 63 years; p = 0.034), while the proportion of admissions due to HCV-cirrhosis was lower in P-II (15.8 % vs 21.6 %; p = 0.041). There were no significant differences in the proportion of admissions due to other etiologies of cirrhosis between both periods. Patients in the P-II group presented an active viral infection (57.1 vs 97.3 %; p = 0.001) less frequently and had a higher rate of excessive alcohol consumption (55.5 vs 30.7 %; p = 0.003) when admitted, while HIV co-infection was less frequent (1.6 % vs 10.7 %; p = 0.039). Conclusion: the proportion of admissions due to decompensated HCV-related cirrhosis has decreased by almost 30 % since the introduction of the DAA. In addition, the characteristics of patients admitted have changed since the application of interferon-free regimens.
Share Button
New comment
Comments
No comments for this article
References
1. Arends JE, Kracht PA, Hoepelman AI. Performance of hepatitis C virus (HCV) direct - acting antivirals in clinical trials and daily practice. Clin Microbiol Infect 2016;22:846-52.
2. Carrat F, Fontaine H, Dorival C, et al. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019;39:1453-64.
3. Berenguer M, de la Rosa Rodríguez G, Domínguez-Gil B. Significant impact of new oral therapies against HCV on the waiting-list for liver transplantation in Spain. J Hepatol 2018;69:966-8.
4. Lohse AW, Mieli-Vergani G. Autoinmune hepatitis. J. Hepatol. 2011;55:171-82.
5. Beuers U, Boberg KM, Chapman RW et al. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. J Hepatol 2009;51:237-67.
6. Mathurin P, Hadengue A, Bataller R et al. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcoholic liver disease. J Hepatol 2012;57:399-420.
7. Ratziu V, Bellentani S, Cortez-Pinto H et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol 2010;53-372-384.
8. McDonald SA, Innes HA, Aspinall E, et al. Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era. J Viral Hepat 2017;24:295-303.
9. Planas R, Ballesté B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40:823-30.
10. Nguyen GC, Segev DL, Thuluvath PJ. Nationwide increase in hospitalizations and hepatitis C among inpatients with cirrhosis and sequelae of portal hypertension. Clin Gastroenterol Hepatol 2007;5:1092-9.
11. McDonald SA, Innes HA, Aspinall EJ, et al. Inpatient hospital burden of hepatitis C-diagnosed patients with decompensated cirrhosis. Liver Int 2018;38:1402-10.
12. Alavi M, Law MG, Valerio H, et al. Declining hepatitis C virus-related live disease burden in the direct-acting antiviral therapy era in New South Wales, Australia. J Hepatol 2019;71:281-8.
13. Deuffic-Burban S, Schwarzinger M, Obach D, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naïve patientes? A cost-effectiveness analysis (ANRS95141). J Hepatol 2014;61:7-14.
14. Turnes J, Domínguez-Hernández R, Casado MA, et al. Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain. Rev Esp Enferm Dig 2017;109:809-17.
15. Nahon P, Bourcier V, Layese R, et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 2017;152:142-56.e2.
16. Backus LI, Belperio PS, Shahoumian TA, et al. Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease. Hepatology 2019;69:487-97.
17. Ioannou GN, Gree PK, Berry K, et al. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2018;68:25-32.
18. Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017;6(6):CD012143. Published 2017 Jun 6. doi:10.1002/14651858.CD012143.pub2.
19. Dang K, Hirode G, Singal AK, et al. Alcoholic liver disease epidemiology in the United States: a retrospective analysis of 3 US databases. Am J Gastoenterol. 2020;115:96-104.
20. Asrani SK, Kouznetsova M, Ogola G, et al. Increasing health care burden of chronic liver disease compared with other chronic diseases, 2004-2013. Gastroenterology. 2018;155:719-29.
21. Zou B, Yeo YH, Jeong D, et al. A Nationwide study of inpatient admissions, mortality, and costs for patients with cirrhosis from 2005 to 2015 in the USA. Dig Dis Sci. 2019 Oct 9. doi: 10.1007/s10620-019-05869-z. [Epub ahead of print]
22. Boerekamps A, Newsum AM, Smit C, et al. High treatment uptake in human immunodeficiency virus/hepatitis C virus-coinfected patients after unrestricted access to direct-acting antivirals in the Netherlands. Clin Infect Dis 2018; 66:1352-9.
23. Moorman AC, Xing J, Ko S, et al. Late diagnosis of hepatitis C virus infection in the Chronic Hepatitis Cohort Study (CheCS): missed opportunities for intervention. Hepatology 2015;61:1479-84.
24. Crespo J, Albillos A, Buti M, et al. Eliminación de la hepatitis C. Documento de posicionamiento de la Asociación Española para el Estudio del Hígado (AEEH). Rev Esp Enferm Dig 2019;11:862-73.
25. Innes HA, Hutchinson SJ, Barclay S, et al. Quantifying the fraction of cirrhosis attributable to alcohol among chronic hepatitis C virus patients: implications for treatment cost-effectiveness. Hepatology 2013;57:451-60.
26. Alavi M, Janjua Nz, Chong M, et al. The contribution of alcohol use disorder to decompensated cirrhosis among people with hepatitis C: an international study. J Hepatol 2018;68:393-401.
Ioannou GN, Green PK, Berry K. Alcohol use and long-term outcomes among U.S. veterans who received Direct-Acting Antivirals for hepatitis C treatment. Hepatol Commun 2020;4:314-24.
Related articles

Original

Hepatitis C in homeless people: reaching a hard-to-reach population

DOI: 10.17235/reed.2021.7737/2020

Citation tools
Fraile López M, Franco L, Álvarez Navascués C, Varela M, Cadahía V, Torner M, et all. Changes in the characteristics of hospital admissions due to decompensated cirrhosis in the era of direct-acting antivirals against hepatitis C virus. 7024/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 2259 visits.
This article has been downloaded 155 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 02/03/2020

Accepted: 22/04/2020

Online First: 04/06/2020

Published: 08/07/2020

Article revision time: 48 days

Article Online First time: 94 days

Article editing time: 128 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology